Viqualine in resistant depression: a double-blind, placebo-controlled trial.
Viqualine dihydrochloride is a new molecule, which possesses strong serotonin reuptake inhibition properties and, at the same time, diazepam-like actions, such as [3H]-diazepam-binding inhibition and antipunishment effect. The drug was administered double-blindly to 10 patients suffering from major depression resistant to previous treatments with tricyclics. The comparison group (10 patients) received placebo. Lorazepam (10 mg/day) was also given to both groups. Viqualine proved to be significantly superior to placebo in the 4th week of treatment on all the three rating scales which were used. Tolerability of viqualine was good both objectively and on subjective grounds.
Faravelli
C
C
Institute of Nervous and Mental Diseases, Florence University Medical School, Italy.
Albanesi
G
G
Sessarego
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011581:Psychological Tests; D011804:Quinolines / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D000928:Antidepressive Agents; D011804:Quinolines; D012702:Serotonin Antagonists; C038919:viqualine; D008140:Lorazepam